Aberrant alternative splicing of purinergic receptor P2RX4 prevents sensitivity towards combinatorial treatment in colorectal and pancreatic cancer
The Journal of Pathology · 2026-09 · 270 (1) · 55-68
DOI: 10.1002/path.70082 ↗At a glance
Journal article in The Journal of Pathology, published online on 2026-06-03. Written by Christoph Steup and 12 co-authors. Institution: Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany. Major MEDLINE topics: Colorectal Neoplasms, Alternative Splicing, Pancreatic Neoplasms, Receptors, Purinergic P2X4. 67 references. The full text is freely available (open access, CC BY 4.0). Funded by: Deutsche Forschungsgemeinschaft, Frankfurt Cancer Institute, Hessen State Ministry for Higher Education, Research and the Arts.
Abstract (original language)
Recently, we suggested the combination of chemotherapy and P2RX4 inhibition as a promising novel therapeutic approach for P2RX4‐expressing epithelial tumors to prevent paracrine resistance. Here, we aimed to assess whether determining P2RX4 expression status in colorectal and pancreatic cancer patients would allow stratification of potentially responsive patients. Therefore, P2RX4 expression levels were determined by RNA sequencing and immunohistochemistry. Subcellular localization of P2RX4 isoforms was analyzed in HeLa cells and patient‐derived tumor organoids. In contrast to its RNA expression profile, P2RX4 protein levels exhibited differential regulation in human colorectal and pancreatic cancer epithelia due to alternative splicing. Interpatient heterogeneity was greater in colorectal cancer than in pancreatic cancer. Notably, these variations in expression did not correlate with overall patient survival. Alternative P2RX4 transcripts gave rise to functionally distinct protein isoforms that differed in subcellular localization and total protein abundance. Only the correctly spliced, canonical P2RX4 isoform was localized to the plasma membrane and was capable of mediating downstream signaling. Accordingly, P2RX4 inhibition in combination with chemotherapy was effective exclusively in patient‐derived tumor organoids expressing the canonical P2RX4 transcript. In summary, immunohistochemical, but not transcriptomic, assessment of P2RX4 expression enabled the prediction of sensitivity to combinatorial treatment and facilitated the identification of patients who may benefit from P2RX4 inhibition during chemotherapy. Given the lower degree of heterogeneity observed in pancreatic cancer, this tumor entity may represent a promising candidate for early‐phase clinical evaluation of chemotherapy combined with P2RX4 inhibition. © 2026 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus, Frankfurt am Main, Germany.
- Goethe University Frankfurt, Department of Medicine I, University Hospital Frankfurt, Frankfurt am Main, Germany.
- Frankfurt Cancer Institute, Goethe University Frankfurt, Frankfurt am Main, Germany.
- Department of Gastroenterology, Hepatology, Infectious diseases and Endocrinology, Hannover Medical School, Hannover, Germany.
- Goethe University Frankfurt, Dr. Senckenberg Institutes of Pathology and Human Genetics (SPH), University Frankfurt, University Hospital Frankfurt, Frankfurt am Main, Germany.
- German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID profiles: Christoph Steup, Julian Dosch, Christopher Dietz-Fricke, Adalbert F de Valk, Dominic Menger, Peter J Wild, Kilian B Kennel, Paul K Ziegler, Florian R Greten
Funding
- Deutsche Forschungsgemeinschaft
- Frankfurt Cancer Institute
- Hessen State Ministry for Higher Education, Research and the Arts
- Mildred-Scheel Nachwuchszentrum
- Mildred-Scheel Postdoctoral Fellowship
- Federal Ministry of Research, Technology and Space (BMFTR)
- Else Kröner-Fresenius-Stiftung
- Hans und Ria Messer-Stiftung
Cite
APA
Steup, C., Dosch, J., Dietz-Fricke, C., Khosraviseftejani, S., Engel, E., Valk, A. F., Menger, D., Welker, P., Wild, P. J., Kennel, K. B., Kantlehner, M., Ziegler, P. K., & Greten, F. R. (2026). Aberrant alternative splicing of purinergic receptor P2RX4 prevents sensitivity towards combinatorial treatment in colorectal and pancreatic cancer. The Journal of Pathology, 270(1), 55-68. https://doi.org/10.1002/path.70082
Vancouver
Steup C, Dosch J, Dietz-Fricke C, Khosraviseftejani S, Engel E, Valk AF, et al. Aberrant alternative splicing of purinergic receptor P2RX4 prevents sensitivity towards combinatorial treatment in colorectal and pancreatic cancer. The Journal of Pathology. 2026;270(1):55-68. doi:10.1002/path.70082
BibTeX
@article{Steup2026,
author = {Steup, Christoph and Dosch, Julian and Dietz-Fricke, Christopher and Khosraviseftejani, Sara and Engel, Esther and Valk, Adalbert F de and Menger, Dominic and Welker, Patrick and Wild, Peter J and Kennel, Kilian B and Kantlehner, Maja and Ziegler, Paul K and Greten, Florian R},
title = {Aberrant alternative splicing of purinergic receptor P2RX4 prevents sensitivity towards combinatorial treatment in colorectal and pancreatic cancer},
journal = {The Journal of Pathology},
year = {2026},
volume = {270},
number = {1},
pages = {55--68},
doi = {10.1002/path.70082}
}
EUVIMED